Nilotinib

Phase 1Completed

1 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Healthy

Conditions

Healthy

Trial Timeline

Jun 1, 2006 → —

NCT ID

NCT00418769

About Nilotinib

Nilotinib is a phase 1 stage product being developed by Novartis for Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT00418769. Target conditions include Healthy.

What happened to similar drugs?

20 of 20 similar drugs in Healthy were approved

Approved (20) Terminated (1) Active (0)

✅mRNA-1273.712ModernaApproved

✅Cholestyramine + Colesevelam HClDaiichi SankyoApproved

✅Cholestyramine + Cholestyramine + TangDaiichi SankyoApproved

✅Olmesartan medoxomil + Irbesartan + ValsartanDaiichi SankyoApproved

✅Perampanel 6 MGEisaiApproved

✅eszopiclone, zolpidem, placeboSumitomo PharmaApproved

✅Listerine Experimental Mouthwash + Colgate Cavity Protection Toothpaste + Listerine Total Care ZeroJohnson & JohnsonApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04559555	Pre-clinical	Completed	—	—	Acute Lymphoblastic Leukemia (ALL)
NCT04498871	Pre-clinical	Completed	—	—	Hypereosinophilic Syndrome (HES)
NCT04518644	Pre-clinical	Completed	—	—	Chronic Myelogenous Leukemia (CML)
NCT02774512	Phase 1	Withdrawn	May 1, 2016	Nov 1, 2017	Colon Cancer
NCT02546674	Approved	Completed	Feb 18, 2016	Mar 25, 2021	Chronic Myeloid Leukemia
NCT02115386	Phase 3	Terminated	Dec 17, 2015	Oct 31, 2016	Philadelphia Positive (Ph+) Chronic Myeloid Leukemia
NCT02353728	Phase 2	Completed	Jan 1, 2015	Feb 1, 2021	Chronic Myeloid Leukemia
NCT02108951	Phase 3	Terminated	Jul 7, 2014	Aug 10, 2016	Philidelphia Positive Chronic Myeloid Leukaemia
NCT01844765	Phase 2	Completed	Aug 20, 2013	Aug 28, 2020	Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia
NCT01744665	Phase 2	Completed	Aug 12, 2013	Sep 29, 2018	CML
NCT01863745	Phase 2	Completed	Jun 25, 2013	Oct 2, 2023	Gastrointestinal Stromal Tumors
NCT03332511	Approved	Completed	May 6, 2013	Oct 24, 2016	Chronic Myeloid Leukemia, Chronic Phase
NCT01743989	Phase 3	Completed	Apr 15, 2013	Jul 8, 2020	Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
NCT01735955	Approved	Completed	Mar 29, 2013	Jul 7, 2023	Chronic Myelogenous Leukemia (CML)
NCT01698905	Phase 2	Completed	Dec 20, 2012	Jan 29, 2025	Chronic Myeloid Leukemia
NCT01562847	Pre-clinical	UNKNOWN	Jul 1, 2011	Jun 1, 2015	Chronic Myeloid Leukemia
NCT01077544	Phase 1	Completed	Apr 14, 2011	Jul 1, 2015	Chronic Myeloid Leukemia
NCT01254188	Phase 3	Completed	Apr 1, 2011	Nov 1, 2014	Chronic Myeloid Leukemia
NCT01274351	Phase 2	Completed	Jan 25, 2011	Aug 1, 2019	Chronic Myelogenous Leukemia
NCT01270893	Phase 2	Withdrawn	Jan 1, 2011	—	Gastrointestinal Cancer

Competing Products

20 competing products in Healthy

See all competitors

Product	Company	Stage	Hype Score
Use of Wearable Digital Sensors After mRNA Vaccination in Adults	Moderna	Preclinical	0
mRNA-0184	Moderna	Phase 1	0
mRNA-6231	Moderna	Phase 1	0
Letrozole	Dr. Reddy's Laboratories	Phase 1	26
Isotretinoin	Dr. Reddy's Laboratories	Phase 1	26
Fexofenadine	Dr. Reddy's Laboratories	Phase 1	26
Sertraline	Dr. Reddy's Laboratories	Phase 1	26
Nizatidine + Axid	Dr. Reddy's Laboratories	Phase 1	26
Anastrozole	Dr. Reddy's Laboratories	Phase 1	26
mRNA-1273.712	Moderna	Approved	0
Risperidone	Dr. Reddy's Laboratories	Phase 1	26
Lamotrigine	Dr. Reddy's Laboratories	Phase 1	26
Metformin + Glucophage	Dr. Reddy's Laboratories	Phase 1	26
Lamotrigine	Dr. Reddy's Laboratories	Phase 1	26
mRNA-0184	Moderna	Phase 1	0
Divalproex Sodium	Dr. Reddy's Laboratories	Phase 1	26
Sirolimus	Dr. Reddy's Laboratories	Phase 1	26
Glimepiride	Dr. Reddy's Laboratories	Phase 1	26
Ziprasidone Hydrochloride	Dr. Reddy's Laboratories	Phase 1	26
Naproxen sodium	Dr. Reddy's Laboratories	Phase 1	26